Anika Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Anika Therapeutics, Inc. (ANIK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 340.31 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-03-03
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was 116.86K shares, a 193.02% increase year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-03-31 was 216.38K shares, a 728.14% increase year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-12-31 was 140.57K shares, a 595.40% increase year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-09-30 was 61.00K shares, a 11.57% increase year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 340.31K shares, a 27.18% increase from fiscal 2024.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 267.58K shares, a 121.43% increase from fiscal 2023.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 120.84K shares, a 39.18% decline from fiscal 2022.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 198.68K shares, a 9.22% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 340.31K shares 10-K · filed 2026-03-03 | ||||
| 2025-06-30 | 116.86K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-05 | 333.24K shares 10-Q · filed 2025-11-05 | 272.47K shares 10-Q · filed 2025-07-30 | 473.81K shares derived: sum of 3 quarters · filed 2025-11-05 | 534.81K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-03-31 | 216.38K shares 10-Q · filed 2025-05-09 | 356.95K shares derived: sum of 2 quarters · filed 2025-05-09 | 417.95K shares derived: sum of 3 quarters · filed 2025-05-09 | 457.83K shares derived: sum of 4 quarters · filed 2025-05-09 | |
| 2024-12-31 | 140.57K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | 201.57K shares derived: sum of 2 quarters · filed 2025-03-17 | 241.46K shares derived: sum of 3 quarters · filed 2025-03-17 | 267.58K shares 10-K · filed 2025-03-17 | |
| 2024-09-30 | 61.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | 100.88K shares derived: sum of 2 quarters · filed 2024-11-04 | 127.01K shares 10-Q · filed 2024-11-04 | 147.22K shares derived: sum of 4 quarters · filed 2024-11-04 | |
| 2024-06-30 | 39.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 66.01K shares 10-Q · filed 2024-08-08 | 86.22K shares derived: sum of 3 quarters · filed 2024-08-08 | 140.90K shares derived: sum of 4 quarters · filed 2024-08-08 | |
| 2024-03-31 | 26.13K shares 10-Q · filed 2024-05-08 | 46.34K shares derived: sum of 2 quarters · filed 2024-05-08 | 101.01K shares derived: sum of 3 quarters · filed 2024-05-08 | 135.76K shares derived: sum of 4 quarters · filed 2024-05-08 | |
| 2023-12-31 | 20.21K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | 74.89K shares derived: sum of 2 quarters · filed 2024-03-15 | 109.63K shares derived: sum of 3 quarters · filed 2024-03-15 | 120.84K shares 10-K · filed 2024-03-15 | |
| 2023-09-30 | 54.67K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | 89.42K shares derived: sum of 2 quarters · filed 2023-11-03 | 100.63K shares 10-Q · filed 2023-11-03 | 142.64K shares derived: sum of 4 quarters · filed 2023-11-03 | |
| 2023-06-30 | 34.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 45.96K shares 10-Q · filed 2023-08-08 | 87.97K shares derived: sum of 3 quarters · filed 2023-08-08 | 113.72K shares derived: sum of 4 quarters · filed 2023-08-08 | |
| 2023-03-31 | 11.21K shares 10-Q · filed 2023-05-09 | 53.22K shares derived: sum of 2 quarters · filed 2023-05-09 | 78.97K shares derived: sum of 3 quarters · filed 2023-05-09 | 162.04K shares derived: sum of 4 quarters · filed 2023-05-09 | |
| 2022-12-31 | 42.01K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 67.76K shares derived: sum of 2 quarters · filed 2023-03-16 | 150.83K shares derived: sum of 3 quarters · filed 2023-03-16 | 198.68K shares 10-K · filed 2023-03-16 | |
| 2022-09-30 | 25.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 108.81K shares derived: sum of 2 quarters · filed 2022-11-09 | 156.67K shares 10-Q · filed 2022-11-09 | 197.93K shares derived: sum of 4 quarters · filed 2022-11-09 | |
| 2022-06-30 | 83.07K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 130.93K shares 10-Q · filed 2022-08-04 | 172.19K shares derived: sum of 3 quarters · filed 2022-08-04 | ||
| 2022-03-31 | 47.86K shares 10-Q · filed 2022-05-06 | 89.12K shares derived: sum of 2 quarters · filed 2022-05-06 | |||
| 2021-12-31 | 41.26K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | 218.87K shares 10-K · filed 2022-03-11 | |||
| 2021-09-30 | 177.60K shares 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |